Safety of Potential Paediatric Patients Treated With Idarucizumab: a Non-internventional Chart Review Study
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Idarucizumab (Primary)
- Indications Blood coagulation disorders; Haemorrhage
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 27 Jan 2017 Planned initiation date changed from 1 Nov 2016 to 1 Mar 2017.
- 06 Jan 2017 Planned initiation date changed from 1 Jun 2016 to 1 Nov 2016.
- 17 Jun 2016 New trial record